![Else Sissel Vorstrup](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Else Sissel Vorstrup
Keine laufenden Positionen mehr
Karriereverlauf von Else Sissel Vorstrup
Ehemalige bekannte Positionen von Else Sissel Vorstrup
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Copenhagen University Hospital | Vorsitzender | 01.01.1995 | - |
University Hospital Telethon | Corporate Officer/Principal | 01.01.2001 | 01.01.2001 |
Lundbeck Foundation
![]() Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | 18.06.2014 | - |
Corporate Officer/Principal | - | - | |
Conrig Pharma ApS
![]() Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - | - |
H. LUNDBECK A/S | Corporate Officer/Principal | 01.01.2001 | - |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | 30.03.2011 | - |
Vorsitzender | 18.07.2012 | 29.11.2013 | |
Independent Dir/Board Member | - | - |
Ausbildung von Else Sissel Vorstrup
The State University of New York | Graduate Degree |
Statistik
International
Dänemark | 6 |
Vereinigte Staaten | 2 |
Kolumbien | 2 |
Operativ
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chairman | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
H. LUNDBECK A/S | Health Technology |
Private Unternehmen | 3 |
---|---|
Lundbeck Foundation
![]() Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Miscellaneous |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Conrig Pharma ApS
![]() Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Else Sissel Vorstrup
- Erfahrung